(Reuters) — Valeant Pharmaceuticals International’s experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.
The FDA is not obliged to follow the advice of its advisory committees but typically does so.